Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges
Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.
You may also be interested in...
Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.
The company believes there is room in the market for its more standard-acting hemophilia A products Kogenate and Kovaltry, as well as a long half-life product like Jivi.
Company explains how it will design upcoming Phase III hemophilia A study of SPK-8011 for success, but some analysts still think it's risky business.